Customizable Alerts Give Dexcom Users a More Flexible, Individualized Diabetes Management Solution
The Dexcom G7 Continuous Glucose Monitoring (CGM) System provides real-time glucose readings and is clinically proven to lower A1C and improve time in range (TIR).1-5
To help achieve this, Dexcom G7 offers customizable alerts to suit an individual's preferences. With alerts that include the Urgent Low Soon Alert, Delay 1st Alert, and Quiet mode, individuals can ensure their sensor provides the best fit for their diabetes management goals and needs.
<Download Customized Alerts Quick Reference PDF>
Unique Urgent Low Soon Alert Can Help Prevent Low Glucose Events
Dexcom is the only CGM brand that provides users with a predictive Urgent Low Soon Alert that can notify them up to 20 minutes before a serious hypoglycemic event at or below 3.1 mmol/L.
This advance notice empowers those using Dexcom G7 to take proactive action and potentially avert a serious low glucose event.
More Customizable Options Give Dexcom G7 Users More Control
The new Delay 1st Alert lets users delay their alert for 15 minutes up to 4 hours. This allows enough time for any recent insulin dose to take effect during or following a meal, making future notifications more relevant.
New to Dexcom G7, Quiet modes are useful when the wearer doesn’t want to hear an audible alert, such as during an exam, meeting, or performance. Quiet modes include both Vibrate and Silence All options.
Both Delay 1st Alert and Quiet modes allow the user greater choice and control over their alert preferences and can help prevent alert fatigue.
Choose Dexcom for A More Personalized CGM Experience
By choosing Dexcom G7, people living with diabetes can enjoy customizable alerts that let them know when it’s time to take action, providing greater peace of mind, more flexibility, and individualized diabetes management.
Use this helpful guide when assisting people to customize their Dexcom G7 alert preferences:
1 Beck RW, et al. JAMA. 2017;317(4):371-378.
2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
3 Martens T, et al. JAMA. 2021;325(22):2262-2272.
4 Laffel LM, et al. JAMA. 2020;323(23):2388-2396.
5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.
MAT-4673 V1.0